11C-Choline PET Guided Salvage Radiation Therapy for Isolated Pelvic and Paraortic Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Rationale and Early Genitourinary or Gastrointestinal Toxicities
Purpose: To assess gastrointestinal (GI) and genitourinary (GU) adverse events (AEs) of 11C-choline-positron emission tomography (CholPET) guided lymph node (LN) radiation therapy (RT) in patients who experience biochemical failure after radical prostatectomy. Methods and Materials: From 2013 to 201...
Main Authors: | , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-10-01
|
Series: | Advances in Radiation Oncology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2452109419300843 |
id |
doaj-8e07834416a34d0eba5035d62d782358 |
---|---|
record_format |
Article |
spelling |
doaj-8e07834416a34d0eba5035d62d7823582020-11-25T01:38:27ZengElsevierAdvances in Radiation Oncology2452-10942019-10-014465966711C-Choline PET Guided Salvage Radiation Therapy for Isolated Pelvic and Paraortic Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Rationale and Early Genitourinary or Gastrointestinal ToxicitiesKrishan R. Jethwa, MD0Christopher D. Hellekson, MD1Jaden D. Evans, MD2William S. Harmsen, MS3Tyler J. Wilhite, MD4Thomas J. Whitaker, PhD5Sean S. Park, MD PhD6C. Richard Choo, MD7Bradley J. Stish, MD8Kenneth R. Olivier, MD9Rimki Haloi, MBBS10Val J. Lowe, MD11Brian T. Welch, MD12J. Fernando Quevedo, MD13Lance A. Mynderse, MD14R.Jeffrey Karnes, MD15Eugene D. Kwon, MD16Brian J. Davis, MD PhD17Department of Radiation Oncology, Rochester, MinnesotaDepartment of Radiation Oncology, Rochester, MinnesotaDepartment of Radiation Oncology, Rochester, MinnesotaBiomedical Statistics and Informatics, Rochester, MinnesotaDepartment of Radiation Oncology, Rochester, MinnesotaDepartment of Radiation Oncology, Rochester, MinnesotaDepartment of Radiation Oncology, Rochester, MinnesotaDepartment of Radiation Oncology, Rochester, MinnesotaDepartment of Radiation Oncology, Rochester, MinnesotaDepartment of Radiation Oncology, Rochester, MinnesotaDepartment of Urology, Mayo Clinic, Rochester, MinnesotaDepartment of Radiology, Rochester, MinnesotaDepartment of Radiology, Rochester, MinnesotaDepartment of Division of Medical Oncology, Mayo Clinic, Rochester, MinnesotaDepartment of Urology, Mayo Clinic, Rochester, MinnesotaDepartment of Urology, Mayo Clinic, Rochester, MinnesotaDepartment of Urology, Mayo Clinic, Rochester, MinnesotaDepartment of Radiation Oncology, Rochester, Minnesota; Corresponding author.Purpose: To assess gastrointestinal (GI) and genitourinary (GU) adverse events (AEs) of 11C-choline-positron emission tomography (CholPET) guided lymph node (LN) radiation therapy (RT) in patients who experience biochemical failure after radical prostatectomy. Methods and Materials: From 2013 to 2016, 107 patients experienced biochemical failure of prostate cancer, had CholPET-detected pelvic and/or paraortic LN recurrence, and were referred for RT. Patients received androgen suppression and CholPET guided LN RT (median dose, 45 Gy) with a simultaneous integrated boost to CholPET-avid sites (median dose, 56.25 Gy), all in 25 fractions. RT-naïve patients had the prostatic fossa included in the initial treatment volumes followed by a sequential boost (median dose, 68 Gy). GI and GU AEs were reported per Common Terminology Criteria for Adverse Events (version 4.0) with data gathered retrospectively. Differences in maximum GI and GU AEs at baseline, immediately post-RT, and at early (median, 4 months) and late (median, 14 months) follow-up were assessed. Results: Median follow-up was 16 months (interquartile range [IQR], 11-25). Median prostate-specific antigen at time of positive CholPET was 2.3 ng/mL (IQR, 1.3-4.8), with a median of 2 (IQR, 1-4) choline-avid LNs per patient. Most recurrences were within the pelvis (53%) or pelvis + paraortic (40%). Baseline rates of grade 1 to 2 GI AEs were 8.4% compared with 51.9% (4.7% grade 2) of patients post-RT (P < .01). These differences resolved by 4-month (12.2%, P = .65) and 14-month AE assessments (9.1%, P = .87). There was no significant change in grade 1 to 2 GU AEs post-RT (64.1%) relative to baseline (56.0%, P = .21), although differences did arise at 4-month (72.2%, P = .01) and 14-month (74.3%, P = .01) AE assessments. Conclusions: Salvage CholPET guided nodal RT has acceptably low rates of acute GI and GU AEs and no significant detriment in 14-month GI AEs. These data are of value in counseling patients and designing prospective trials evaluating the oncologic efficacy of this treatment strategy.http://www.sciencedirect.com/science/article/pii/S2452109419300843 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Krishan R. Jethwa, MD Christopher D. Hellekson, MD Jaden D. Evans, MD William S. Harmsen, MS Tyler J. Wilhite, MD Thomas J. Whitaker, PhD Sean S. Park, MD PhD C. Richard Choo, MD Bradley J. Stish, MD Kenneth R. Olivier, MD Rimki Haloi, MBBS Val J. Lowe, MD Brian T. Welch, MD J. Fernando Quevedo, MD Lance A. Mynderse, MD R.Jeffrey Karnes, MD Eugene D. Kwon, MD Brian J. Davis, MD PhD |
spellingShingle |
Krishan R. Jethwa, MD Christopher D. Hellekson, MD Jaden D. Evans, MD William S. Harmsen, MS Tyler J. Wilhite, MD Thomas J. Whitaker, PhD Sean S. Park, MD PhD C. Richard Choo, MD Bradley J. Stish, MD Kenneth R. Olivier, MD Rimki Haloi, MBBS Val J. Lowe, MD Brian T. Welch, MD J. Fernando Quevedo, MD Lance A. Mynderse, MD R.Jeffrey Karnes, MD Eugene D. Kwon, MD Brian J. Davis, MD PhD 11C-Choline PET Guided Salvage Radiation Therapy for Isolated Pelvic and Paraortic Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Rationale and Early Genitourinary or Gastrointestinal Toxicities Advances in Radiation Oncology |
author_facet |
Krishan R. Jethwa, MD Christopher D. Hellekson, MD Jaden D. Evans, MD William S. Harmsen, MS Tyler J. Wilhite, MD Thomas J. Whitaker, PhD Sean S. Park, MD PhD C. Richard Choo, MD Bradley J. Stish, MD Kenneth R. Olivier, MD Rimki Haloi, MBBS Val J. Lowe, MD Brian T. Welch, MD J. Fernando Quevedo, MD Lance A. Mynderse, MD R.Jeffrey Karnes, MD Eugene D. Kwon, MD Brian J. Davis, MD PhD |
author_sort |
Krishan R. Jethwa, MD |
title |
11C-Choline PET Guided Salvage Radiation Therapy for Isolated Pelvic and Paraortic Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Rationale and Early Genitourinary or Gastrointestinal Toxicities |
title_short |
11C-Choline PET Guided Salvage Radiation Therapy for Isolated Pelvic and Paraortic Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Rationale and Early Genitourinary or Gastrointestinal Toxicities |
title_full |
11C-Choline PET Guided Salvage Radiation Therapy for Isolated Pelvic and Paraortic Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Rationale and Early Genitourinary or Gastrointestinal Toxicities |
title_fullStr |
11C-Choline PET Guided Salvage Radiation Therapy for Isolated Pelvic and Paraortic Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Rationale and Early Genitourinary or Gastrointestinal Toxicities |
title_full_unstemmed |
11C-Choline PET Guided Salvage Radiation Therapy for Isolated Pelvic and Paraortic Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Rationale and Early Genitourinary or Gastrointestinal Toxicities |
title_sort |
11c-choline pet guided salvage radiation therapy for isolated pelvic and paraortic nodal recurrence of prostate cancer after radical prostatectomy: rationale and early genitourinary or gastrointestinal toxicities |
publisher |
Elsevier |
series |
Advances in Radiation Oncology |
issn |
2452-1094 |
publishDate |
2019-10-01 |
description |
Purpose: To assess gastrointestinal (GI) and genitourinary (GU) adverse events (AEs) of 11C-choline-positron emission tomography (CholPET) guided lymph node (LN) radiation therapy (RT) in patients who experience biochemical failure after radical prostatectomy. Methods and Materials: From 2013 to 2016, 107 patients experienced biochemical failure of prostate cancer, had CholPET-detected pelvic and/or paraortic LN recurrence, and were referred for RT. Patients received androgen suppression and CholPET guided LN RT (median dose, 45 Gy) with a simultaneous integrated boost to CholPET-avid sites (median dose, 56.25 Gy), all in 25 fractions. RT-naïve patients had the prostatic fossa included in the initial treatment volumes followed by a sequential boost (median dose, 68 Gy). GI and GU AEs were reported per Common Terminology Criteria for Adverse Events (version 4.0) with data gathered retrospectively. Differences in maximum GI and GU AEs at baseline, immediately post-RT, and at early (median, 4 months) and late (median, 14 months) follow-up were assessed. Results: Median follow-up was 16 months (interquartile range [IQR], 11-25). Median prostate-specific antigen at time of positive CholPET was 2.3 ng/mL (IQR, 1.3-4.8), with a median of 2 (IQR, 1-4) choline-avid LNs per patient. Most recurrences were within the pelvis (53%) or pelvis + paraortic (40%). Baseline rates of grade 1 to 2 GI AEs were 8.4% compared with 51.9% (4.7% grade 2) of patients post-RT (P < .01). These differences resolved by 4-month (12.2%, P = .65) and 14-month AE assessments (9.1%, P = .87). There was no significant change in grade 1 to 2 GU AEs post-RT (64.1%) relative to baseline (56.0%, P = .21), although differences did arise at 4-month (72.2%, P = .01) and 14-month (74.3%, P = .01) AE assessments. Conclusions: Salvage CholPET guided nodal RT has acceptably low rates of acute GI and GU AEs and no significant detriment in 14-month GI AEs. These data are of value in counseling patients and designing prospective trials evaluating the oncologic efficacy of this treatment strategy. |
url |
http://www.sciencedirect.com/science/article/pii/S2452109419300843 |
work_keys_str_mv |
AT krishanrjethwamd 11ccholinepetguidedsalvageradiationtherapyforisolatedpelvicandparaorticnodalrecurrenceofprostatecancerafterradicalprostatectomyrationaleandearlygenitourinaryorgastrointestinaltoxicities AT christopherdhelleksonmd 11ccholinepetguidedsalvageradiationtherapyforisolatedpelvicandparaorticnodalrecurrenceofprostatecancerafterradicalprostatectomyrationaleandearlygenitourinaryorgastrointestinaltoxicities AT jadendevansmd 11ccholinepetguidedsalvageradiationtherapyforisolatedpelvicandparaorticnodalrecurrenceofprostatecancerafterradicalprostatectomyrationaleandearlygenitourinaryorgastrointestinaltoxicities AT williamsharmsenms 11ccholinepetguidedsalvageradiationtherapyforisolatedpelvicandparaorticnodalrecurrenceofprostatecancerafterradicalprostatectomyrationaleandearlygenitourinaryorgastrointestinaltoxicities AT tylerjwilhitemd 11ccholinepetguidedsalvageradiationtherapyforisolatedpelvicandparaorticnodalrecurrenceofprostatecancerafterradicalprostatectomyrationaleandearlygenitourinaryorgastrointestinaltoxicities AT thomasjwhitakerphd 11ccholinepetguidedsalvageradiationtherapyforisolatedpelvicandparaorticnodalrecurrenceofprostatecancerafterradicalprostatectomyrationaleandearlygenitourinaryorgastrointestinaltoxicities AT seansparkmdphd 11ccholinepetguidedsalvageradiationtherapyforisolatedpelvicandparaorticnodalrecurrenceofprostatecancerafterradicalprostatectomyrationaleandearlygenitourinaryorgastrointestinaltoxicities AT crichardchoomd 11ccholinepetguidedsalvageradiationtherapyforisolatedpelvicandparaorticnodalrecurrenceofprostatecancerafterradicalprostatectomyrationaleandearlygenitourinaryorgastrointestinaltoxicities AT bradleyjstishmd 11ccholinepetguidedsalvageradiationtherapyforisolatedpelvicandparaorticnodalrecurrenceofprostatecancerafterradicalprostatectomyrationaleandearlygenitourinaryorgastrointestinaltoxicities AT kennethroliviermd 11ccholinepetguidedsalvageradiationtherapyforisolatedpelvicandparaorticnodalrecurrenceofprostatecancerafterradicalprostatectomyrationaleandearlygenitourinaryorgastrointestinaltoxicities AT rimkihaloimbbs 11ccholinepetguidedsalvageradiationtherapyforisolatedpelvicandparaorticnodalrecurrenceofprostatecancerafterradicalprostatectomyrationaleandearlygenitourinaryorgastrointestinaltoxicities AT valjlowemd 11ccholinepetguidedsalvageradiationtherapyforisolatedpelvicandparaorticnodalrecurrenceofprostatecancerafterradicalprostatectomyrationaleandearlygenitourinaryorgastrointestinaltoxicities AT briantwelchmd 11ccholinepetguidedsalvageradiationtherapyforisolatedpelvicandparaorticnodalrecurrenceofprostatecancerafterradicalprostatectomyrationaleandearlygenitourinaryorgastrointestinaltoxicities AT jfernandoquevedomd 11ccholinepetguidedsalvageradiationtherapyforisolatedpelvicandparaorticnodalrecurrenceofprostatecancerafterradicalprostatectomyrationaleandearlygenitourinaryorgastrointestinaltoxicities AT lanceamyndersemd 11ccholinepetguidedsalvageradiationtherapyforisolatedpelvicandparaorticnodalrecurrenceofprostatecancerafterradicalprostatectomyrationaleandearlygenitourinaryorgastrointestinaltoxicities AT rjeffreykarnesmd 11ccholinepetguidedsalvageradiationtherapyforisolatedpelvicandparaorticnodalrecurrenceofprostatecancerafterradicalprostatectomyrationaleandearlygenitourinaryorgastrointestinaltoxicities AT eugenedkwonmd 11ccholinepetguidedsalvageradiationtherapyforisolatedpelvicandparaorticnodalrecurrenceofprostatecancerafterradicalprostatectomyrationaleandearlygenitourinaryorgastrointestinaltoxicities AT brianjdavismdphd 11ccholinepetguidedsalvageradiationtherapyforisolatedpelvicandparaorticnodalrecurrenceofprostatecancerafterradicalprostatectomyrationaleandearlygenitourinaryorgastrointestinaltoxicities |
_version_ |
1725053712315973632 |